Table 6. Summary of denosumab treatment in children and adolescents in the literature.

Disease	Dose and interval of denosumab	Preparation before start denosumab	Supplements in therapy	Monitoring in therapy	Dose modifications	Monitoring after end of therapy
ABC	<45 kg 70 mg/m2 every month; ≥45 kg 120 mg every month	Treat and prevent oral diseases; correct hypocalcemia and vitamin D deficiency	Calcium 500 mg/day, vitamin D 400 IU/day	Serum calcium ≥2 mmol/L and ≤2.9 mmol/L	Hold denosumab when serum calcium <2 mmol/L or if denosumab-related grade 3 or 4 adverse events occur	Monitoring calcium >6 months, if symptomatic hypercalcemia is observed, decrease doses every 3 months
GCTB
CGCG
FD	1–1.5 mg/kg every month
OI	1 mg/kg every 3 months

ABC, aneurysmal bone cyst; GCTB, giant cell tumor of bone; CGCG, central giant cell granuloma; FD, fibrous dysplasia; OI, osteogenesis imperfecta.